Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) ...

Merck and AstraZeneca have seen their share prices surge after Bristol-Myers Squibb suffered a major setback with Opdivo in non-small cell lung cancer (NSCLC). BMS announced on Friday that Opdivo ...

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...

Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...

Bristol Myers Squibb (BMS) has shared positive overall survival (OS) results from a late-stage study of its Opdivo (nivolumab) combination in non-small cell lung cancer (NSCLC).

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its checkpoint inhibitors Opdivo and Yervoy, when combined, reduced the risk of disease progression or death by 38% in a Phase 3 trial for ...

Squibb announced the final analysis of overall survival, or OS, from the Phase 3 CheckMate -816 study, which evaluated ...

Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 million stock ...

Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used with platinum-doublet ...